Update on heparin: what do we need to know?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Thrombosis and Thrombolysis

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11239-009-0411-6PMID 19882363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Otamixaban in acute coronary syndromes.

  2009cited by this paper
• Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.

  2009cited by this paper
• Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues

  2009cited by this paper
• Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.

  2009cited by this paper
• New Antithrombotic Drugs

  2009cited by this paper
• Heparin-induced thrombocytopenia: What clinicians need to know

  2009cited by this paper
• Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials

  2009cited by this paper
• Outbreak of adverse reactions associated with contaminated heparin.

  2008cited by this paper
• Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

  2008cited by this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.

  2008cited by this paper
• Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy

  2008cited by this paper
• Home versus in-patient treatment for deep vein thrombosis.

  2007cited by this paper
• Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.

  2007cited by this paper
• Idraparinux versus standard therapy for venous thromboembolic disease.

  2007cited by this paper
• Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia

  2007cited by this paper
• The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.

  2007cited by this paper
• Extended prophylaxis of venous thromboembolism with idraparinux.

  2007cited by this paper
• First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity

  2006cited by this paper
• Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency

  2006cited by this paper
• Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular- Weight Heparin for Acute Treatment of Venous Thromboembolism

  2006cited by this paper
• Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

  2006cited by this paper
• Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

  2006cited by this paper
• Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.

  2006influential reference
• Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies

  2006cited by this paper
• Heparin Synergistically Enhances Interleukin-11 Signaling through Up-regulation of the MAPK Pathway*

  2006cited by this paper
• Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro

  2005cited by this paper
• Minimising the risk of heparin-induced osteoporosis during pregnancy

  2005cited by this paper
• Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

  2005cited by this paper
• Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

  2005cited by this paper
• Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis

  2004cited by this paper
• Fondaparinux or enoxaparin for initial treatment of symptomatic deep venous thrombosis: Randomized trial

  2004cited by this paper
• Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites.

  2003cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.

  2003cited by this paper
• Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide*

  2003cited by this paper
• Secondary prophylaxis with warfarin for venous thromboembolism.

  2003cited by this paper
• Localization of the Heparin Binding Exosite of Factor IXa*

  2002cited by this paper
• Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

  2001cited by this paper
• Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.

  2001cited by this paper
• Home versus in-patient treatment for deep vein thrombosis.

  2001cited by this paper
• A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.

  2000cited by this paper
• Low molecular weight heparins

  2000influential reference
• Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis.

  2000cited by this paper
• [New antithrombotic drugs].

  1999cited by this paper
• The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro

  1998cited by this paper
• Low-molecular-weight heparins.

  1997cited by this paper
• A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.

  1997cited by this paper
• Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.

  1996cited by this paper
• Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin

  1994cited by this paper
• A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.

  1994cited by this paper
• The Weight-based Heparin Dosing Nomogram Compared with a Standard Care Nomogram

  1993cited by this paper
• Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins

  1993cited by this paper
• Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance

  1992cited by this paper
• The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects.

  1987cited by this paper

• Anticoagulant therapy in orthopedic surgery – a review on anticoagulant agents, risk factors, monitoring, and current challenges

  2024cites this paper
• Synthesis, Biological Evaluation and Reversal of Sulfonated Di‐ and Triblock Copolymers as Novel Parenteral Anticoagulants

  2024cites this paper
• Pharmacology of Heparin and Related Drugs: An Update

  2023cites this paper
• Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters

  2023cites this paper
• Inhibition of platelet-surface-bound proteins during coagulation under flow II: Antithrombin and heparin

  2022cites this paper
• Polysaccharide-based bioactive adsorbents for blood-contacting implant devices

  2022cites this paper
• Prehospital unfractionated heparin and primary percutaneous coronary intervention

  2021cites this paper
• Fibrin and Extracellular Matrix: Scaffolds and Network for Malignant Cells

  2021cites this paper
• Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.

  2021cites this paper
• Positive Effect of Bemiparin to Blood Flow

  2020cites this paper
• Transfusion characteristics and hemostatic conditions in octogenarians undergoing emergency surgery for acute aortic dissection: a retrospective study

  2020cites this paper
• Platelets in Advanced Chronic Kidney Disease: Two Sides of the Coin

  2020cites this paper
• [Sustainable anticoagulation in COVID-19: Review of severity prediction and clinical reasoning].

  2020cites this paper
• Chemically Modified Biopolymers for the Formation of Biomedical Hydrogels.

  2020cites this paper
• Individual variation in unfractionated heparin dosing after pediatric cardiac surgery

  2020cites this paper
• Prehospital unfractionated heparin prior to primary PCI

  2020cites this paper
• Examination of Laboratory for Monitoring Heparin Anticoagulant Therapy

  2019cites this paper
• Thromboprophylaxis

  2019cites this paper
• Hemostasis, Surgical Bleeding, and Transfusion

  2019cites this paper
• Synthesis, characterization and anticoagulant activity of chitosan derivatives

  2019cites this paper
• Utilization and Outcomes of Children Treated with Direct Thrombin Inhibitors on Paracorporeal Ventricular Assist Device Support.

  2019cites this paper
• USE OF ANTICOAGULANTS IN CEREBRAL VASCULAR PATHOLOGY

  2019cites this paper
• Unfractionated Heparin and Low-Molecular-Weight Heparin

  2018cites this paper
• Low-molecular-weight sulfonated chitosan as template for anticoagulant nanoparticles

  2018influential citation
• Therapeutic strategies to target microbial protein-glycosaminoglycan interactions.

  2018cites this paper
• A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making

  2018cites this paper
• Pro-angiogenic Molecules for Therapeutic Angiogenesis.

  2017cites this paper
• Glycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice

  2017cites this paper
• The Role of Tinzaparin in Oncology

  2017cites this paper
• Heparin for the prevention of intraventricular haemorrhage in preterm infants.

  2016cites this paper
• Formal Synthesis of Anticoagulant Drug Fondaparinux Sodium.

  2016cites this paper
• Pharmacology of anticoagulants used in the treatment of venous thromboembolism

  2016cites this paper
• Qualitative and Quantitative Analysis of Heparin during Precipitation byNear-Infrared Spectroscopy

  2016cites this paper
• Anticoagulant Therapy to Prevent Embolization

  2016cites this paper
• Pharmacology of Heparin and Related Drugs

  2016cites this paper
• Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism

  2016cites this paper
• Qualitative and Quantitative Analysis of Heparin during Precipitation by Near-Infrared Spectroscopy

  2016cites this paper
• The Effect of Administration Protocol of Subcutaneous Enoxaparin Injection on Formation of Ecchymosis

  2016cites this paper
• Development and validation of a simple and sensitive size-exclusion chromatography method for quantitative determination of heparin in pharmaceuticals

  2015cites this paper
• NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology‐oncology

  2015cites this paper
• Re-visiting the structure of heparin.

  2015cites this paper
• TGFβ functionalized starPEG-heparin hydrogels modulate human dermal fibroblast growth and differentiation.

  2015cites this paper
• Trends in the development of oral anticoagulants.

  2015cites this paper
• Directed polyvalent display of sulfated ligands on virus nanoparticles elicits heparin-like anticoagulant activity.

  2014cites this paper
• Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

  2014cites this paper
• Urgent reversal of anticoagulation

  2014cites this paper
• Epidurals in Patients Receiving Thromboprophylaxis with Unfractionated Heparin Three Times a Day: The Value of Activated Partial Thromboplastin Time Testing

  2014cites this paper
• Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux

  2014cites this paper
• New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal

  2014cites this paper
• Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner.

  2014cites this paper
• Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage

  2014cites this paper
• Biodegradable hydrogels by physical and enzymatic crosslinking of biomacromolecules

  2013cites this paper
• Obstetrical Management of an Extremely Overweight Pregnant Woman (184 kg bw) with Special Attention on Thromboprophylaxis

  2013cites this paper
• Anticoagulants: A Review of the Pharmacology, Dosing, and Complications

  2013cites this paper
• Heparin and other anticoagulants in amniotic fluid embolism (AFE): Literature review and concept of the therapy

  2013cites this paper
• Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

  2013cites this paper
• CARACTERIZAÇÃO E ATIVIDADE ANTICOAGULANTE DE POLISSACARÍDEOS SULFATADOS EXTRAÍDOS DA ALGA MARROM Dictyopteris justii

  2012cites this paper
• Newer anticoagulants in critically ill patients.

  2012cites this paper
• Chapter 4 – Hemostasis, Surgical Bleeding, and Transfusion

  2012cites this paper
• Therapeutischer Nutzen von niedermolekularem Heparin bei Frauen mit rezidivierenden Aborten

  2012cites this paper
• Six almost unknown reasons why LMWH is better than unfractionated heparin in therapy of patients with present or threatening heart failure

  2011cites this paper
• A novel factor Xa inhibitor (PifXa) is an effective, reversible inhibitor of blood coagulation

  2011cites this paper
• Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

  2011cites this paper
• Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.

  2011cites this paper
• Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

  2011cites this paper
• Faster , Safer , Better : The New Paradigm for Managing ST-Segment Elevation Myocardial Infarction

  2011influential citation
• Heterofucans from the Brown Seaweed Canistrocarpus cervicornis with Anticoagulant and Antioxidant Activities

  2011cites this paper
• THROMBOPHILIA AND DIRECT THROMBIN INHIBITOR LEPIRUDIN - CLINICAL AND MONITORING ASPECTS

  2010cites this paper
• Chitosan derivatives as novel potential heparin reversal agents.

  2010cites this paper
• A study of some lipid-based drug delivery systems

  2010cites this paper